Charles River Laboratories Q3 EPS rises to $6.86

PUBT · 1d ago
Charles River Laboratories Q3 EPS rises to $6.86
  • Charles River Laboratories’ third-quarter 2026 GAAP diluted earnings per share rose year-over-year to $6.86.
  • Earnings included a $245.6 million benefit from reversing acquired tax reserves following new tax legislation and completion of foreign tax requirements.
  • Revenue fell year-over-year to $982.7 million, primarily due to the May 2026 divestitures.
  • CEO Birgit Girshick reported continued robust year-over-year increases in Discovery and Safety Assessment net bookings and proposals.
  • The company raised its 2026 GAAP earnings guidance to $8.15–$8.35 per share, primarily due to the acquired tax reserve reversal.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charles River Laboratories International Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261104526679) on November 04, 2026, and is solely responsible for the information contained therein.